玻璃体内注射贝伐单抗成功治疗脉络膜骨瘤合并的脉络膜新生血管。

Successful treatment of choroidal neovascularization complicating a choroidal osteoma with intravitreal bevacizumab.

作者信息

Rao Sunil, Gentile Ronald C

机构信息

From the *Department of Ophthalmology, The New York Eye and Ear Infirmary, New York, New York; and †Department of Ophthalmology, New York Medical College, Valhalla, New York.

出版信息

Retin Cases Brief Rep. 2010 Fall;4(4):303-5. doi: 10.1097/ICB.0b013e3181aff523.

DOI:10.1097/ICB.0b013e3181aff523

PMID:25390904

Abstract

PURPOSE

To report the effect of off-label use of bevacizumab (Avastin) in the treatment of choroidal neovascularization associated with a choroidal osteoma.

METHODS

Interventional case report examining antivascular endothelial growth factor therapy used for choroidal neovascularization complicating a choroidal osteoma.

RESULTS

A 24-year-old man with a choroidal osteoma presented with metamorphopsia and decreased vision in his left eye of 20/60. Clinical examination, fluorescein angiography, B-scan ultrasonography, and optical coherence tomography revealed a well-circumscribed macular choroidal osteoma with overlying subretinal hemorrhage and a choroidal neovascular membrane. The patient was treated with a series of 3 intravitreal bevacizumab (Avastin) injections (1.25 mg/0.05 mL) performed at baseline, 1 month, and 2 months. Treatment resulted in resolution of subretinal hemorrhage and fluid with improvement in visual acuity to 20/30 at the 5-month follow-up.

CONCLUSION

Intravitreal bevacizumab seems to be a promising treatment for choroidal neovascularization (CNV) associated with choroidal osteomas.

摘要

目的

报告贝伐单抗（阿瓦斯汀）非标签使用治疗脉络膜骨瘤相关脉络膜新生血管的效果。

方法

介入性病例报告，研究用于脉络膜骨瘤并发脉络膜新生血管的抗血管内皮生长因子治疗。

结果

一名患有脉络膜骨瘤的24岁男性，左眼出现视物变形，视力下降至20/60。临床检查、荧光素血管造影、B超超声检查和光学相干断层扫描显示，有一个边界清晰的黄斑脉络膜骨瘤，其上有视网膜下出血和脉络膜新生血管膜。患者在基线、1个月和2个月时接受了3次玻璃体内注射贝伐单抗（阿瓦斯汀）（1.25毫克/0.05毫升）的治疗。治疗导致视网膜下出血和积液消退，在5个月的随访中视力提高到20/30。